Project description
Drug discovery efforts for pulmonary hypertension
Pulmonary arterial hypertension (PAH) is a rare disorder associated with high blood pressure in the vessels that supply the lungs. Most drugs address the induced vasoconstriction caused by the narrowing or obstruction in the small arteries in the lung. Recent evidence indicates that inhibitors against Rho-associated protein kinases (ROCKs) may benefit PAH patients by targeting vascular remodelling and inflammation in the lungs. The scope of the EU-funded MS4Drug project is to characterise the conformational changes in ROCKs in vitro as well as in the cellular environment induced by such inhibitors. Alongside investigation into the molecular mechanisms underlying the signalling pathways of ROCKs, researchers hope to design improved drugs for PAH.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- natural scienceschemical sciencesanalytical chemistrymass spectrometry
- natural sciencesbiological sciencesmolecular biologystructural biology
Programme(s)
Funding Scheme
MSCA-IF-EF-SE - Society and Enterprise panel
Coordinator
43122 Parma
Italy
See on map